Mariarosaria Miloso

Via Cadore 48, MB
Monza, 20900, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Correction: Malacrida et al. Another Brick to Confirm the Efficacy of Rigosertib as Anticancer Agent. Int. J. Mol. Sci. 2023, 24, 1721.

Correction: Malacrida et al. Another Brick to Confirm the Efficacy of Rigosertib as Anticancer Agent. Int. J. Mol. Sci. 2023, 24, 1721.

Journal: International journal of molecular sciences

Published: June 25, 2026

From lichen to organoids: Usnic acid enantiomers show promise against Cholangiocarcinoma via MNK2 targeting and MAPK pathway modulation.

From lichen to organoids: Usnic acid enantiomers show promise against Cholangiocarcinoma via MNK2 targeting and MAPK pathway modulation.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: April 04, 2025

Neurodegeneration: can metabolites from Eremurus persicus help?

Neurodegeneration: can metabolites from Eremurus persicus help?

Journal: Frontiers in pharmacology

Published: October 08, 2023

Another Brick to Confirm the Efficacy of Rigosertib as Anticancer Agent.

Another Brick to Confirm the Efficacy of Rigosertib as Anticancer Agent.

Journal: International journal of molecular sciences

Published: November 30, 2022

From Nature to Synthetic Compounds: Novel 1(N),2,3 Trisubstituted-5-oxopyrrolidines Targeting Multiple Myeloma Cells.

From Nature to Synthetic Compounds: Novel 1(N),2,3 Trisubstituted-5-oxopyrrolidines Targeting Multiple Myeloma Cells.

Journal: International journal of molecular sciences

Published: October 03, 2022

Evaluation of antitumoral effect of Hibiscus sabdariffa extract on human breast cancer cells.

Evaluation of antitumoral effect of Hibiscus sabdariffa extract on human breast cancer cells.

Journal: Biochemistry and biophysics reports

Published: April 29, 2022

Rigosertib and Cholangiocarcinoma: A Cell Cycle Affair.

Rigosertib and Cholangiocarcinoma: A Cell Cycle Affair.

Journal: International journal of molecular sciences

Published: November 30, 2021

Anti-Multiple Myeloma Potential of Secondary Metabolites from Hibiscus sabdariffa-Part 2.

Anti-Multiple Myeloma Potential of Secondary Metabolites from Hibiscus sabdariffa-Part 2.

Journal: Molecules (Basel, Switzerland)

Published: October 08, 2021

In Vitro Evaluation of Rigosertib Antitumoral and Radiosensitizing Effects against Human Cholangiocarcinoma Cells.

In Vitro Evaluation of Rigosertib Antitumoral and Radiosensitizing Effects against Human Cholangiocarcinoma Cells.

Journal: International journal of molecular sciences

Published: May 04, 2021

Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-7.

Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-7.

Journal: Molecules (Basel, Switzerland)

Published: June 16, 2020

Exploring the RC-106 Chemical Space: Design and Synthesis of Novel (E)-1-(3-Arylbut-2-en-1-yl)-4-(Substituted) Piperazine Derivatives as Potential Anticancer Agents.

Exploring the RC-106 Chemical Space: Design and Synthesis of Novel (E)-1-(3-Arylbut-2-en-1-yl)-4-(Substituted) Piperazine Derivatives as Potential Anticancer Agents.

Journal: Frontiers in chemistry

Published: March 19, 2020

3D proteome-wide scale screening and activity evaluation of a new ALKBH5 inhibitor in U87 glioblastoma cell line.

3D proteome-wide scale screening and activity evaluation of a new ALKBH5 inhibitor in U87 glioblastoma cell line.

Journal: Bioorganic & medicinal chemistry

Published: September 24, 2019

Showing 1-12 of 26

Last Updated: 09/26/2026